Skip to main content
Erschienen in: World Journal of Surgery 2/2021

26.10.2020 | Original Scientific Report

Analysis of Patient Outcome after Non-curative Resection for Hepatocellular Carcinoma Using Nationwide Survey Data in Japan

verfasst von: Taku Aoki, Keiichi Kubota, Shoji Kubo, Susumu Eguchi, Namiki Izumi, Norihiro Kokudo, Michiie Sakamoto, Shuichiro Shiina, Tadatoshi Takayama, Osamu Nakashima, Yutaka Matsuyama, Takamichi Murakami, Masatoshi Kudo

Erschienen in: World Journal of Surgery | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Non-curative (debulking) hepatic resection for hepatocellular carcinoma (HCC) is occasionally applied for selected cases with bulky tumors or for oncologic emergency cases; however, the clinical usefulness of this procedure has not yet been fully evaluated. The aim of the present study was to evaluate the patient outcomes of non-curative hepatic resections for HCC using data from bi-annual nationwide surveys conducted in Japan.

Method

Data of 1084 non-curative hepatic resections for HCC were collected. The patient outcomes were compared with those of curative resections, transcatheter arterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC).

Results

Patient survival after the non-curative resection was poorer than that after curative resection (P < 0.001) and was especially dismal in cases with extrahepatic tumor spread (lymph node metastasis, peritoneal seeding, or distant metastasis). As compared to cases receiving TACE without surgery, non-curative resections for multiple intrahepatic tumors were applied to cases with advanced tumors with good liver functional reserve. The survival outcomes were significantly more favorable in the TACE group, but the results became similar after propensity score matching of the patients. The survival outcome of patients receiving non-curative resections was better than that of cases treated by HAIC, with median survival times of 26.0 months and 10.0 months, respectively.

Conclusion

The indications for non-curative hepatic resection in patients with HCC should be judged cautiously, especially in patients with extrahepatic tumor spread. This treatment approach may be beneficial for selected patients with intermediate- or advanced-stage HCC limited in liver and with good liver functional reserve.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: source, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-386CrossRef Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: source, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-386CrossRef
2.
Zurück zum Zitat Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRef Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRef
3.
Zurück zum Zitat Kokudo T, Hasegawa K, Matsuyama Y et al (2017) Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology 66:510–517CrossRef Kokudo T, Hasegawa K, Matsuyama Y et al (2017) Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology 66:510–517CrossRef
4.
Zurück zum Zitat Kukudo T, Hasegawa K, Matsuyama Y et al (2016) Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol 65:938–943CrossRef Kukudo T, Hasegawa K, Matsuyama Y et al (2016) Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol 65:938–943CrossRef
5.
Zurück zum Zitat Aoki T, Kokudo N, Matsuyama Y et al (2014) Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg 259:532–542CrossRef Aoki T, Kokudo N, Matsuyama Y et al (2014) Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg 259:532–542CrossRef
6.
Zurück zum Zitat Lai ECH, Tang CN, Ha JPY et al (2008) Cytoreductive surgery in multidisciplinary treatment of advanced hepatocellular carcinoma. ANZ Surg 78:504–507CrossRef Lai ECH, Tang CN, Ha JPY et al (2008) Cytoreductive surgery in multidisciplinary treatment of advanced hepatocellular carcinoma. ANZ Surg 78:504–507CrossRef
7.
Zurück zum Zitat Hasegawa K, Makuuchi M, Kokudo N et al (2014) Impact of histologically confirmed lymph node metastases on patient survival after surgical resection for hepatocellular carcinoma: report of a Japanese nationwide survey. Ann Surg 259:166–170CrossRef Hasegawa K, Makuuchi M, Kokudo N et al (2014) Impact of histologically confirmed lymph node metastases on patient survival after surgical resection for hepatocellular carcinoma: report of a Japanese nationwide survey. Ann Surg 259:166–170CrossRef
8.
Zurück zum Zitat Hai S, Hatano E, Okada T et al (2018) Is noncurative hepatic resection justified for advanced hepatocellular carcinoma? Am Surg 84:1938–1944CrossRef Hai S, Hatano E, Okada T et al (2018) Is noncurative hepatic resection justified for advanced hepatocellular carcinoma? Am Surg 84:1938–1944CrossRef
9.
Zurück zum Zitat Obi S, Yoshida H, Toune R et al (2006) Combination therapy of intraarterial 5-fuluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106:1990–1997CrossRef Obi S, Yoshida H, Toune R et al (2006) Combination therapy of intraarterial 5-fuluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106:1990–1997CrossRef
10.
Zurück zum Zitat Nouso K, Miyahara K, Uchida D et al (2013) Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan. Br J Cancer 109:1904–1907CrossRef Nouso K, Miyahara K, Uchida D et al (2013) Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan. Br J Cancer 109:1904–1907CrossRef
11.
Zurück zum Zitat Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRef Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRef
12.
Zurück zum Zitat Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66CrossRef Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66CrossRef
13.
Zurück zum Zitat Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173CrossRef Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173CrossRef
Metadaten
Titel
Analysis of Patient Outcome after Non-curative Resection for Hepatocellular Carcinoma Using Nationwide Survey Data in Japan
verfasst von
Taku Aoki
Keiichi Kubota
Shoji Kubo
Susumu Eguchi
Namiki Izumi
Norihiro Kokudo
Michiie Sakamoto
Shuichiro Shiina
Tadatoshi Takayama
Osamu Nakashima
Yutaka Matsuyama
Takamichi Murakami
Masatoshi Kudo
Publikationsdatum
26.10.2020
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 2/2021
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-020-05830-6

Weitere Artikel der Ausgabe 2/2021

World Journal of Surgery 2/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.